107 related articles for article (PubMed ID: 15996830)
1. Incidence of plasma cell dyscrasia as a second primary malignancy may be low in postmenopausal breast cancer survivors treated with selective estrogen receptor modulator or aromatase inhibitor.
Altundag K; Kurt M; Islam R; Altundag O; Turen S
Med Hypotheses; 2006; 66(2):444-5. PubMed ID: 15996830
[No Abstract] [Full Text] [Related]
2. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
Tuxen MK; Nielsen DL; Lindberg H; Kamby C
Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
[TBL] [Abstract][Full Text] [Related]
3. [Neoadjuvant antihormonal treatment of women with breast cancer].
Tuxen MK; Kamby C; Nielsen DL
Ugeskr Laeger; 2007 Sep; 169(37):3077-81. PubMed ID: 17877952
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant endocrine treatment of early breast cancer.
Lønning PE
Hematol Oncol Clin North Am; 2007 Apr; 21(2):223-38. PubMed ID: 17512446
[TBL] [Abstract][Full Text] [Related]
5. Novel concepts for the chemoprevention of breast cancer through aromatase inhibition.
Kendall A; Dowsett M
Endocr Relat Cancer; 2006 Sep; 13(3):827-37. PubMed ID: 16954432
[TBL] [Abstract][Full Text] [Related]
6. Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant tamoxifen.
Booth CM; Pater JL; Goss PE
Cancer; 2007 May; 109(9):1927-8; author reply 1928. PubMed ID: 17354227
[No Abstract] [Full Text] [Related]
7. [Adjuvant treatment of breast cancer. Endocrine therapy].
Mouridsen HT; Andersen J
Ugeskr Laeger; 2007 Sep; 169(37):3072-6. PubMed ID: 17877951
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive breast cancer.
Seo JH; Kim YH; Kim JS
Cancer Chemother Pharmacol; 2009 Jan; 63(2):261-6. PubMed ID: 18365197
[TBL] [Abstract][Full Text] [Related]
9. Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators.
Dunn BK; Ryan A
Ann N Y Acad Sci; 2009 Feb; 1155():141-61. PubMed ID: 19250201
[TBL] [Abstract][Full Text] [Related]
10. Aromatase inhibitors: a time for reflection.
Birge SJ
Menopause; 2007; 14(6):971-2. PubMed ID: 17975522
[No Abstract] [Full Text] [Related]
11. Hormonal therapy for postmenopausal breast cancer: the science of sequencing.
Miller WR; Bartlett JM; Canney P; Verrill M
Breast Cancer Res Treat; 2007 Jun; 103(2):149-60. PubMed ID: 17039263
[TBL] [Abstract][Full Text] [Related]
12. Sequential therapy with tamoxifen and aromatase inhibitors in early-stage postmenopausal breast cancer: a review of the evidence.
Litsas G
Oncol Nurs Forum; 2008 Jul; 35(4):714-21. PubMed ID: 18591176
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen and aromatase inhibitors differentially affect vascular endothelial growth factor and endostatin levels in women with breast cancer.
Holmes CE; Huang JC; Pace TR; Howard AB; Muss HB
Clin Cancer Res; 2008 May; 14(10):3070-6. PubMed ID: 18483373
[TBL] [Abstract][Full Text] [Related]
14. Regression of chronic lymphocytic leukemia with aromatase inhibitor-letrozole?
Paydas S
Leuk Res; 2009 Apr; 33(4):566-7. PubMed ID: 18585780
[No Abstract] [Full Text] [Related]
15. Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer.
Dixon JM
Expert Rev Anticancer Ther; 2008 Mar; 8(3):453-63. PubMed ID: 18366292
[TBL] [Abstract][Full Text] [Related]
16. Hormonal breast cancer agents: implications for the primary care provider.
Lyon DE; Roux G; Voll S
J Am Acad Nurse Pract; 2006 Nov; 18(11):518-23. PubMed ID: 17064329
[TBL] [Abstract][Full Text] [Related]
17. Endocrine therapy for breast cancer: an overview.
Cheung KL
Breast; 2007 Aug; 16(4):327-43. PubMed ID: 17499991
[TBL] [Abstract][Full Text] [Related]
18. Optimising adjuvant endocrine treatment of breast cancer with aromatase inhibitors.
Fentiman IS
Int J Clin Pract; 2006 Jun; 60(6):689-93. PubMed ID: 16805754
[TBL] [Abstract][Full Text] [Related]
19. New agents in development for breast cancer.
Gao XP; Liu F
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):68-74. PubMed ID: 17218855
[TBL] [Abstract][Full Text] [Related]
20. Chemoprevention of breast cancer.
Castrellon AB; Glück S
Expert Rev Anticancer Ther; 2008 Mar; 8(3):443-52. PubMed ID: 18366291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]